Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: A comparative review

Chronic kidney disease presents a health challenge that has a complex underlying pathophysiology, both acquired and inherited. The pharmacotherapeutic treatment options available today lower the progression of the disease and improve the quality of life but cannot completely cure it. This poses a ch...

Full description

Saved in:
Bibliographic Details
Main Author: Saeed Alshahrani (Author)
Format: Book
Published: Frontiers Media S.A., 2023-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_966fade1f8564a5f81355b9b1a29d0f6
042 |a dc 
100 1 0 |a Saeed Alshahrani  |e author 
245 0 0 |a Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: A comparative review 
260 |b Frontiers Media S.A.,   |c 2023-02-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2023.1101068 
520 |a Chronic kidney disease presents a health challenge that has a complex underlying pathophysiology, both acquired and inherited. The pharmacotherapeutic treatment options available today lower the progression of the disease and improve the quality of life but cannot completely cure it. This poses a challenge to the healthcare provider to choose, from the available options, the best way to manage the disease as per the presentation of the patient. As of now, the recommended first line of treatment to control the blood pressure in chronic kidney disease is the administration of renin-angiotensin-aldosterone system modulators. These are represented mainly by the direct renin inhibitor, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. These modulators are varied in their structure and mechanisms of action, hence showing varying treatment outcomes. The choice of administration of these modulators is determined by the presentation and the co-morbidities of the patient, the availability and affordability of the treatment option, and the expertise of the healthcare provider. A direct head-to-head comparison between these significant renin-angiotensin-aldosterone system modulators is lacking, which can benefit healthcare providers and researchers. In this review, a comparison has been drawn between the direct renin inhibitor (aliskiren), angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. This can be of significance for healthcare providers and researchers to find the particular loci of interest, either in structure or mechanism, and to intervene as per the case presentation to obtain the best possible treatment option. 
546 |a EN 
690 |a hypertension 
690 |a aliskiren 
690 |a angiotensin-converting enzyme inhibitors 
690 |a angiotensin II receptor blockers 
690 |a chronic kidney disease 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 14 (2023) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2023.1101068/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/966fade1f8564a5f81355b9b1a29d0f6  |z Connect to this object online.